BRANCHAMIN 4% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BRANCHAMIN 4% IN PLASTIC CONTAINER (BRANCHAMIN 4% IN PLASTIC CONTAINER).
BRANCHAMIN 4% is a branched-chain amino acid (BCAA) solution providing leucine, isoleucine, and valine. It serves as a substrate for protein synthesis and energy metabolism in muscle tissue, particularly during stress or starvation. BCAAs regulate protein turnover by stimulating insulin secretion and mTOR signaling, thereby promoting anabolism and reducing catabolism.
| Metabolism | Primarily transaminated to their corresponding keto acids in muscle, liver, and other tissues, followed by oxidative decarboxylation via branched-chain alpha-keto acid dehydrogenase complex. Metabolites enter the TCA cycle for energy production. |
| Excretion | Renal elimination of infused amino acids; negligible biliary/fecal excretion. Typically >90% of infused nitrogen is excreted renally as urea and ammonia. |
| Half-life | Branched-chain amino acids (BCAAs) have short half-lives: leucine ~0.5-2 h, isoleucine ~1-2 h, valine ~1-2 h. In hepatic impairment, half-life may be prolonged. |
| Protein binding | Minimal (<10%); amino acids are not significantly bound to plasma proteins. |
| Volume of Distribution | Approximately 0.4-0.6 L/kg; distributes primarily in total body water. |
| Bioavailability | Intravenous: 100% (only route of administration). Not applicable orally for this formulation. |
| Onset of Action | Intravenous infusion: metabolic effects (e.g., reduction of aromatic amino acids) begin within 1-2 hours; clinical improvement in hepatic encephalopathy may be seen within 24-48 hours. |
| Duration of Action | Intravenous infusion: effects last as long as infusion is maintained; after discontinuation, plasma BCAA levels decline rapidly (within hours). No sustained effect. |
Intravenous infusion of 500 mL to 1000 mL per day, administered at a rate not exceeding 100 mL/hour. Typical dose: 7-10 mL/kg/day.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73m²). For moderate impairment (eGFR 30-59 mL/min/1.73m²), reduce dose by 50% and monitor serum amino acids. |
| Liver impairment | Contraindicated in decompensated liver cirrhosis or hepatic encephalopathy (Child-Pugh class C). For Child-Pugh class A or B, use with caution and reduce dose by 25-50% based on tolerance. |
| Pediatric use | Weight-based dosing: 2.5-5 mL/kg/day by intravenous infusion, not to exceed 100 mL/hour. Adjust based on metabolic and nutritional needs. |
| Geriatric use | No specific dose adjustment required but start at lower end of dosing range (e.g., 500 mL/day) due to potential reduced renal function and comorbidities. Monitor fluid and electrolyte balance closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BRANCHAMIN 4% IN PLASTIC CONTAINER (BRANCHAMIN 4% IN PLASTIC CONTAINER).
| Breastfeeding | Compatible with breastfeeding; amino acids are normal milk constituents. M/P ratio not applicable. |
| Teratogenic Risk | No teratogenic effects reported; amino acids are essential nutrients. No known risk in any trimester. |
| Fetal Monitoring | Monitor maternal electrolytes, acid-base balance, fluid status, and liver/renal function. Assess for signs of hyperammonemia in neonates if maternal toxicity occurs. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to any component","Severe electrolyte imbalances or fluid overload","Maple syrup urine disease (MSUD) due to defective BCAA metabolism","Uncontrolled metabolic acidosis"]
| Precautions | ["Risk of metabolic acidosis if administered with inadequate sodium or potassium","Monitor serum amino acid levels and electrolytes in patients with renal or hepatic impairment","Use with caution in patients with hyperammonemia as BCAAs may exacerbate ammonia production","Intravenous administration may cause thrombophlebitis; use in-line filter and change administration site every 24 hours"] |
| Food/Dietary | No direct food interactions. However, patients on parenteral nutrition should not consume oral food unless specified by their dietitian, as this solution is used when oral intake is inadequate or contraindicated. Avoid high-protein oral supplements without medical advice, as they may worsen hepatic encephalopathy. |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility. |
| Clinical Pearls | BRANCHAMIN 4% is a branched-chain amino acid (BCAA) solution used for parenteral nutrition in patients with hepatic encephalopathy or severe liver disease. It should be administered via central line due to high osmolarity. Monitor serum ammonia, electrolytes, and renal function. Do not use as a sole source of nutrition; must be part of a balanced amino acid regimen. Rate of infusion should be adjusted to avoid rapid rise in BUN. |
| Patient Advice | This medication is given through an IV line to provide essential amino acids when you cannot eat normally. · Report any signs of infection at the IV site, such as redness, swelling, or pain. · You may need regular blood tests to monitor your liver and kidney function. · Do not change the infusion rate or stop the medication without consulting your healthcare provider. · Inform your doctor if you have diabetes, as this solution may affect blood sugar levels. |